Trial Profile
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2017
Price :
$35
*
At a glance
- Drugs Vapendavir (Primary)
- Indications Asthma; Rhinovirus infections
- Focus Therapeutic Use
- Acronyms RHINO
- Sponsors Biota Pharmaceuticals
- 08 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
- 28 Mar 2012 Primary endpoint 'Wisconsin-Upper-Respiratory-Symptom-Survey' has been met, according to a Biota Holdings media release.
- 28 Mar 2012 Status changed from active, no longer recruiting to completed, according to a Biota Holdings media release.